A new class of Indole-based HDAC8 inhibitors as potential anti-lung cancer agents: In silico design, synthesis, biological assessment and binding interaction analysis

Key Points

• The aim is to develop and assess a new series of indole-based HDAC8 inhibitors for lung cancer treatment.
• Designed and synthesized indole-based hydroxamic acids
• Conducted in silico analyses including QSAR and chemical space networks
• Performed biological assessments to evaluate effectiveness against lung cancer
• Identified several promising HDAC8 inhibitors with significant anti-cancer activity
• Showed strong binding interactions with HDAC8
• Demonstrated enhanced efficacy in preclinical models of lung cancer